<DOC>
	<DOCNO>NCT02091492</DOCNO>
	<brief_summary>This study test hypothesis daily subcuaneous administration 20µg teriparatide ( TPTD ) compare daily subcuaneous placebo twelve week accelerate proximal 2-segment humerus fracture heal improves three dimensional structural property bone measure via quantitative bone image analysis finite element model assessed quantitative compute tomography .</brief_summary>
	<brief_title>Teriparatide Fracture Repair Humans</brief_title>
	<detailed_description>1 . Primary objective : The primary objective quantitative assessment fracture healing ( 2-segment proximal humerus frafcture ) treatment ( daily teriapratide 20µg subcitaneous injection 12 week ) placebo group ( daily placebo subcutaneous injection 12 week ) base compute tomography data ( QCT ; baseline 12 week ) computational analysis three simensional bone structure fracture zone . Bone structure assess mean quantize bone texture characteristic ( callus formation , improvement trabecualar cortical bone structure ) vicinity fracture . 2 . Secondary objective : 2.1.Detection quantification change bone mineralization fracture site baseline QCT scan follow-up QCT scan ( plan interval : 12 week ) use 3-D texture-based cluster analysis two group . 2.2 Evaluation bone strength variation proximal humerus measurement biomechanical property ( stiffness , strength , damage ) base Finite Element ( FE ) technique two group . 2.3.Baseline characterization osteoporotic study population : age , sex , concomitant disease , serum marker bone formation bone resorption , serum colecalciferol level . 2.4.Evaluation fast bone formation resorption marker baseline 3 month follow TPDT placebo group . 2.5.Assessment quality life improvement TPTD placebo group EQ-5D questionnaire ( measurement every 4 week ) . 2.6.Assessment pain reduction TPTD placebo group visual analog scale ( VAS ) 12 week ( measurement every 4 week ) . 2.7.Assessment functional test 3 6 month ( functional testing score ( ASES Score : `` American Shoulder Elbow Surgeon Score '' ) 2.8.Dual energy x-ray absorptiometry ( DXA ) bone mineral density ( BMD ) measurement lumbar spine early change geometrical hip parameter ( cross sectional area - CSA , cross sectional moment inertia - CSMI ) , hip BMD ( femoral neck total hip area ) total body ( lean mass , fat mass , total body BMD ) 2.9 . Number Participants Adverse Events Measure Safety Tolerability</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Humeral Fractures</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>recent proximal 2segment humerus fracture ( 08 day post fracture ) surgical treatment fracture site sign informed consent postmenopausal female male patient age 60 85 year establish osteoporosis define BMD measure DXAtechnology ( dual energy Xray absorptiometry ) Tscore ≤ 2.0 spine hip Hypersensitivity active substance excipients . Preexisting hypercalcemia Severe renal impairment ( eGFR &lt; 35ml/min ) Metabolic bone disease ( include hyperparathyroidism Paget 's disease bone ) primary osteoporosis glucorticoidinduced osteoporosis . Unexplained elevation alkaline phosphatase Prior external beam implant radiation therapy skeleton Patients skeletal malignancy bone metastasis exclude treatment teriparatide . prior antiresorptive therapy ( oral/intravenous bisphosphonates , RANKLantibody , SERMs ) prior strontium ranelate therapy prior TPTD PTH 184 therapy malignancy ≤ 5 year except basalioma hypo/hypercalcemia baseline 25OH vitamin D3 level ≤10 ng/ml prosthesis fracture contralateral humerus</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Proximal humerus fracture , teriparatide</keyword>
</DOC>